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Abstract 
Hundreds of patients with autosomal recessive, complete IL-12p40 or IL-12Rβ1 deficiency 
have been diagnosed over the last 20 years. They typically suffer from invasive 
mycobacteriosis and, occasionally, from mucocutaneous candidiasis. Susceptibility to 
these infections is thought to be due to impairments of IL-12-dependent IFN-g immunity, 
and IL-23-dependent IL-17A/IL-17F immunity, respectively. We report here patients with 
autosomal recessive, complete IL-12Rb2 or IL-23R deficiency, lacking responses to IL-12 
or IL-23 only, all of whom, surprisingly, display mycobacteriosis without candidiasis. We 
show that ab T, gd T, B, NK, ILC1, and ILC2 cells from healthy donors preferentially 
produce IFN-g in response to IL-12, whereas NKT, MAIT, and ILC3 cells preferentially 
produce IFN-g in response to IL-23. We also show that the development of IFN-g-
producing CD4+ T cells, including, in particular, mycobacterium-specific Th1* cells 
(CD45RA–CCR6+), is dependent on both IL-12 and IL-23. Finally, we show that IL12RB1, 
IL12RB2, and IL23R have similar frequencies of deleterious variants in the general 
population. The comparative rarity of symptomatic patients with IL-12Rb2 or IL-23R 
deficiency, relative to IL-12Rb1 deficiency, is, therefore, due to lower clinical penetrance. 
These experiments of Nature show that human IL-12 and IL-23 are both crucial for IFN-g-
dependent immunity to mycobacteria, both individually and much more so cooperatively.   
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  Introduction 
 Life-threatening infectious diseases during the course of infection in otherwise 
healthy individuals can result from single-gene inborn errors of immunity (1, 2). Mendelian 
susceptibility to mycobacterial disease (MSMD) is characterized by severe disease upon 
exposure to weakly virulent mycobacteria, such as Mycobacterium bovis-Bacille Calmette-
Guérin (BCG) vaccines and environmental mycobacteria (3, 4). Affected patients are also 
at risk of severe infections with M. tuberculosis, Salmonella, and, more rarely, other 
intramacrophagic bacteria, fungi, and parasites (4). All known genetic etiologies of MSMD 
affect IFN-g-mediated immunity (4, 5). 
 The most common etiology is autosomal recessive (AR) IL-12Rβ1 deficiency, 
which has been reported in over 200 kindreds since 1998 and has probably been diagnosed 
in many more (4, 6–9). IL-12Rβ1 deficiency displays incomplete clinical penetrance for 
MSMD, and can also underlie monogenic tuberculosis in families with no history of 
infection with environmental mycobacteria or BCG (4, 7, 10). IL-12Rβ1 dimerizes with 
IL-12Rβ2 to form the IL-12 receptor (11), or with IL-23R to form the IL-23 receptor (12). 
IL12B encodes the p40 subunit common to both IL-12 (with p35) and IL-23 (with p19) 
(13). Consistently, AR IL12p40 deficiency, which has been reported in over 50 kindreds, 
is a clinical phenocopy of IL-12Rβ1 deficiency (4, 14).  
 Both IL-12 immunity and IL-23 immunity are abolished in these two disorders. 
Unlike other etiologies of MSMD, these two disorders can also underlie chronic 
mucocutaneous candidiasis (CMC), which is seen in about 25% of patients, due to impaired 
IL-17A/IL-17F-mediated immunity (6, 15–17). Indeed, all known genetic etiologies of 
isolated or syndromic CMC affect IL-17A/IL-17F (16, 18–22). Studies of mouse models 
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have suggested that disruption of the IL-12-IFN-g circuit, particularly in CD4+ helper T 
cells (Th1), underlies mycobacteriosis in these patients, whereas disruption of the IL-23-
IL-17 circuit, particularly in Th17 cells, underlies candidiasis (13). However, the respective 
contributions of human IL-12 and IL-23 to IFN-g-dependent MSMD and IL-17A/F-
dependent CMC have remained elusive in the absence of inborn errors of IL-12p35, IL-
12Rβ2, IL-23p19, or IL-23R.  
 
 Results 
 Homozygous IL12RB2 and IL23R variants in two MSMD kindreds 
We searched for rare, biallelic, non-synonymous and splice variants of IL12A, 
IL12RB2, IL23A, and IL23R, by whole-exome sequencing (WES) in patients with 
unexplained MSMD only (n=555), CMC only (n=214), or both MSMD and CMC (n=27). 
We identified two MSMD kindreds with mutations of IL12RB2 or IL23R. Kindred A (Fig 
1A) is a consanguineous Turkish family, the proband of which (P1; 7.6% homozygosity; 
Fig 1A) had MSMD (Case Reports, SOM, Fig. S1A). Kindred B (Fig. 1B) is a 
consanguineous Iranian family with two MSMD-affected children (P4 and P5; 3.5% of 
homozygosity for P5, Fig. 1B, Fig. S1B-D). These two kindreds were analyzed 
independently, by a combination of WES and genome-wide linkage (GWL) analysis (Fig. 
S1E, F). In kindred A, the c.412C>T mutation of IL12RB2 results in a premature stop codon 
(Q138X) upstream from the segment encoding the transmembrane domain of IL-12Rb2 
(Fig. 1C). In kindred B, the c.344G>A mutation of IL23R results in the C115Y substitution, 
at a key residue in the extracellular domain of IL-23R (23) (Fig. 1D). The IL12RB2 and 
IL23R loci are located in tandem on chromosome 1, and within the largest MSMD-linked 
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chromosomal regions in kindreds A and B, respectively (Fig. S1E-G). The three MSMD 
patients are homozygous for the mutant alleles (Fig. 1A-B, Fig. S1H-I). Incomplete clinical 
penetrance for MSMD was observed in kindred A, as IL12RB2-homozygous and BCG-
vaccinated individual II.3 (P2; 9.1% of homozygosity) had tuberculosis but not MSMD, 
and II.4 (P3; 10.8% of homozygosity) had neither (Case Reports, SOM). None of the five 
homozygous mutant individuals from kindreds A (P1-P3) and B (P4-P5) had ever 
displayed signs of CMC. Principal component analysis (PCA) based on WES data 
confirmed the ancestries of these patients (Fig S1J) (24). The IL12RB2 Q138X mutation 
was reported in the heterozygous state in two of 123,098 individuals in the gnomAD 
database (http://gnomad.broadinstitute.org), whereas the IL23R C115Y mutation was not 
reported in any of the 122,998 individuals sequenced at this site. These mutations were not 
found in a cohort of 3,869 individuals of Middle Eastern descent with neurological diseases 
(data not shown). Finally, both variants have CADD scores well above their respective 
MSCs (25, 26). These data suggested that MSMD patients from kindreds A and B had AR 
deficiencies of IL-12Rb2 and IL-23R, respectively, the former disorder displaying 
incomplete penetrance for MSMD. 
 
The IL12RB2 and IL23R mutant alleles are loss-of-function 
We assessed the expression and function of these mutant alleles, by using 
retrovirus-mediated gene transfer to express C-terminal V5-tagged wild-type (WT) or 
mutant IL-12Rb2 or IL-23R proteins in a B-lymphocyte cell line (LCL) that expressed 
STAT3 and IL-12Rb1 and was engineered to express STAT4IRES-GFP  in a stable manner 
(referred to here as LCL-BSTAT4 cells) (27). The IL12RB2 Q138X mutation resulted in 
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abundant IL-12Rb2 mRNA production (Fig. S1K), but the corresponding protein was 
undetectable (Fig. 1E, Fig. S1L). The IL23R C115Y mutation did not alter the amount of 
mRNA (Fig. S1K) or protein detected (Fig. 1F, Fig. S1L). However, the mutant IL-23R 
protein did not undergo normal N-glycosylation (Fig. 1F) and was much less abundant on 
the cell surface than the exogenous WT protein (Fig. 1G, Fig. S1M). Next, we stimulated 
the LCL-BSTAT4 cells expressing either the WT or mutant IL-12Rb2 and IL-23R proteins 
with IL-12, IL-23, or IFN-α as a positive control. Human IL-12-dependent signaling via 
IL-12Rb1/IL-12Rb2 results in STAT4 activation, whereas IL-23-dependent signaling via 
IL-12Rb1/IL-23R preferentially results in STAT3 activation, although STAT4 may also 
be activated (13). LCL-BSTAT4 cells expressing WT, but not mutant IL-12Rb2, displayed 
STAT4 phosphorylation in response to IL-12 (Fig. 1H). Similarly, the expression of WT 
IL-23R, but not mutant IL-23R, conferred responsiveness to IL-23, as assessed by the level 
of phosphorylation of STAT3 (Fig. 1I) and STAT4 (Fig. S2A) and their upstream Janus 
kinases TYK2 and JAK2 (Fig. S2B). Cells expressing WT, but not mutant IL-12Rb2 or 
IL-23R, also produced CXCL10 in response to IL-12 or IL-23 stimulation, respectively 
(Fig. S2C). Pretreatment of the cells with kifunensine, an inhibitor of glycosylation that 
can rescue mild misfolding and gain-of-glycosylation mutants (28), did not restore the 
function of IL-23R C115Y, suggesting that the mutation is severely deleterious (Fig. S2D). 
Thus, the Q138X IL12RB2 and C115Y IL23R mutant alleles are completely loss-of-
function (LOF) for the IL-12 and IL-23 signaling pathways, respectively, at least in these 
experimental conditions. These experiments demonstrated the role of each mutant allele 
cDNA over-expressed in isolation. Our next set of experiments used patient-derived cells, 
which capture the effects of the patients’ full genotypes at these loci in the context of their 
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own genome. 
 
Autosomal recessive IL-12Rb2 and IL-23R complete deficiencies 
We assessed the expression and function of IL-12Rb2 and IL-23R in patient-
derived cell lines. Herpesvirus saimiri-transformed T (HVS-T) cells from a healthy control, 
P1 (IL-12Rb2 Q138X), and an IL-12Rb1-deficient patient (4) were left unstimulated, or 
stimulated with IL-12 or IFN-a. The healthy control cell line, but not cells from P1 or the 
IL-12Rb1-deficient patient, displayed STAT4 phosphorylation in response to IL-12 (Fig. 
1J). This defect was confirmed in HVS-T cells from P2 and P3 (Fig. S2E). Furthermore, 
the retroviral transduction of P1 cells with WT IL12RB2 restored STAT4 phosphorylation 
in response to IL-12, whereas retrovirus-mediated transduction with an empty vector did 
not (Fig. 1J). In parallel, EBV-B cells from a healthy control, P4 (IL-23R C115Y), and an 
IL-12Rb1-deficient patient were left unstimulated, or were stimulated with IL-23 or IFN-
a. Control EBV-B cells responded to IL-23 by phosphorylating STAT3, whereas cells from 
P4 and the IL-12Rb1-deficient patient did not (Fig. 1K). The transduction of EBV-B cells 
from P4 with WT IL23R rescued both the weak IL-23R expression on the surface of P4 
EBV-B cells (Fig. S2F-G), and the defective IL-23 response (Fig. 1K, Fig S2H), whereas 
retrovirus-mediated transduction with an empty vector did not. IL-12Rb1- and TYK2-
deficient cells were used as negative controls for the IL-23- and IFN-a-dependent 
phosphorylation of STAT3, respectively (Fig. S2H). The IL-23 response was not restored 
by the prior treatment of EBV-B cells from P4 with kifunensine (Fig. S2I-J). Thus, the 
patients from kindreds A and B had complete forms of AR IL-12Rb2 deficiency and AR 
IL-23R deficiency, respectively. 
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IL12RB1, IL12RB2, and IL23R have not evolved under purifying selection 
The much smaller number of biallelic mutations responsible for MSMD found in 
IL12RB2 and IL23R than in IL12RB1 suggested that IL12RB2 and IL23R might have 
evolved under stronger selective constraints, preventing the accumulation of monoallelic 
deleterious variants. We tested this hypothesis by estimating the levels of purifying 
selection acting on all human genes with a generalized linear mixed model approach, 
comparing protein-coding polymorphisms and divergence data (29). Exome data from the 
1,000 Genomes project (30) were aligned with the chimpanzee reference genome, yielding 
exploitable data for a total of 18,969 protein-coding genes (Methods, SOM). The 
proportion of non-deleterious amino-acid variants (f) was estimated at 46.7% for IL12RB1 
[95% confidence interval: 30.4%–71.7%], 61.7% for IL12RB2 [95%CI: 42.1%–90.3%], 
and 49.0% for IL23R [95%CI: 31.1%–77.4%] (Table S1). These three genes were among 
the 50% least constrained genes, and their high levels of amino acid-altering 
polymorphisms, relative to divergence, were consistent with the action of weak negative 
selection (as shown by the negative estimates for the population selection coefficient γ), as 
observed for most human protein-coding genes. Moreover, the neutrality index (NI) and 
gene damage index (GDI, (31)) of IL12RB1, IL12RB2, and IL23R were intermediate (Fig. 
2A-B). The results were similar when looking at alternative parameters of selection such 
as RVIS (32) and f (33) (data not shown). Consistently, numerous missense and predicted 
LOF variants of IL12RB1, IL12RB2, and IL23R are present, in the heterozygous state, in 
gnomAD (Fig. S3A-C). There are also fewer homozygous missense variants for these three 
genes (Fig. 2C-D, Fig. S3D). Overall, this computational study suggested that neither 
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IL12RB2 nor IL23R had evolved under purifying selection, or even under strong negative 
selection, and that they were no less mutated than IL12RB1 in the general population. These 
findings support the alternative hypothesis that the paucity of MSMD patients with IL-
12Rβ2 or IL-23R deficiency, relative to the number of patients identified with IL-12Rβ1 
deficiency, results from lower clinical penetrance for MSMD.  
 
Null mutations in IL12RB1, IL12RB2 and IL23R are rare 
We tested these computational predictions through experimental determinations of 
the actual frequency of IL12RB2 and IL23R LOF mutations in the general population, by 
using the same retroviral system to express all previously untested variants of both genes 
present in the homozygous state in gnomAD (Fig. 2C-D, Fig. S3E-F), in LCL-BSTAT4 cells. 
All homozygous IL12RB1 variants present in the general population that have been tested 
(6 of 16) have been shown to be neutral (34). We stimulated the LCL-BSTAT4 cells 
expressing either the WT or homozygous gnomAD variants of IL-12Rb2 (15 variants) and 
IL-23R (13 variants) proteins with IL-12, IL-23, or IFN-α as a positive control. The 
IL12RB2 mutation L130S encoded a protein that was expressed (Fig. S3G) but not 
functional (Fig. 2E). The L130S mutation of IL12RB2 was found to be present in the 
homozygous state in 1 of 123,092 individuals in the gnomAD database. The IL12RB2 
K649N mutation affects a splice site, and may, therefore, cause a missense or splicing 
mutation, resulting in the deletion of exon 15 (Dex15) (Fig S3H-I). The IL12RB2 K649N 
mutation was found to encode a protein that was both expressed (Fig. S3G) and functional 
(Fig. 2E), like the WT protein, whereas the IL12RB2 Dex15 mutation encoded a protein 
with a lower molecular weight (Fig. S3G) that was non-functional (Fig. 2E). The IL12RB2 
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K649N mutation was identified in 1 of 138,539 individuals in the gnomAD database. None 
of the IL23R mutations tested resulted in a complete loss of protein expression or function 
(Fig. S3J, Fig. 2F). These and previous data (34) suggest that homozygous complete LOF 
mutations of IL12RB2, IL23R and IL12RB1 occur in the general population at a frequency 
of <1 in 100,000 individuals. This frequency is similar to that of autosomal recessive IL-
12Rb1 deficiency, the penetrance of which for MSMD reaches a plateau of about 80% in 
adults (6, 7). 
 
In vivo Th development in IL-12Rb2 and IL-23R deficiency 
 As a first approach to testing the hypothesis that IL-12Rb2 and IL-23R deficiencies 
have a lower clinical penetrance for MSMD than IL-12Rb1 deficiency, we set out to 
decipher the cellular basis of MSMD in patients with these disorders. In humans and mice, 
IL-12 and IL-23 are thought to promote mutually exclusive CD4+ T-helper cell fates (13). 
Before testing for IL-12- and IL-23-dependent effects on the differentiation of human Th 
cells, we compared the frequencies of leukocyte subsets in healthy controls, an IL12RB2 
Q138X patient, an IL23R C115Y patient, and at least one IL-12Rb1-deficient patient. The 
frequencies of innate lymphoid cells (ILCs), B, NK, gd T, total T (CD3+), CD4+ ab T, 
CD8+ ab T, Treg, and TFH cells were normal in patients of all genotypes (Fig. S4A). Patients 
with IL-12Rb2-, IL-23R-, or IL-12Rb1-deficiency had a low frequency of MAIT cells (Fig. 
S4A), consistent with previous findings for IL-12Rb1- and STAT3-deficient patients (35). 
The frequency of naïve cells in the CD4+ and CD8+ T-cell populations was higher, and that 
of memory cells was lower in IL-12Rb2-, IL-23R-, and IL-12Rb1-deficient patients than 
in healthy controls (Fig. 3A, left panel, Fig. S4B-C). IL-12Rb2-, IL-23R-, and IL-12Rb1-
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deficient patients had lower frequencies of memory Th1 (CXCR3+CCR6–) and Th1* 
(CXCR3+CCR6+) cells than healthy controls, IL-12Rb1-deficient patients also had lower 
frequencies of Th17 (CCR4+CCR6+) cells, and the frequency of Th2 (CCR4+CCR6–) cells 
was similar in patients of all genotypes (Fig. 3A, right panel). However, within the CD4+ 
memory compartment, the percentages of Th1* and Th17 cells were low in some IL-
12Rb1-deficient patients, but not in IL-12Rb2- or IL-23R-deficient patients, whereas Th1 
and Th2 percentages were normal in patients of all genotypes (Fig. S4D). These surprising 
findings suggested that isolated deficiencies of IL-12 or IL-23 responses had similar and 
slightly milder consequences, in terms of Th1, Th1*, and perhaps Th17 development, than 
a combined deficiency. 
 
 In vitro Th differentiation in IL-12Rb2 and IL-23R deficiency 
We then investigated the effects of IL-12 and IL-23 signaling defects on the 
generation of CD4+ T-cell subsets upon stimulation with polarizing cytokines in vitro. 
Naïve (CD45RA+CCR7+) CD4+ T cells from healthy donors, IL-12Rβ2-, IL-23R-, and IL-
12Rβ1-deficient patients were purified and cultured under Th0 (non-polarizing) or “Th1”-
, “Th2”- or “Th17”-polarizing conditions (36), and the production of various cytokines was 
measured in culture supernatants with cytometric bead arrays or by ELISA. “Th1” 
differentiation in vitro, which occurs in the presence of IL-12 and is assessed by monitoring 
IFN-g production, was abolished in cells from IL-12Rβ2- and IL-12Rβ1-deficient patients, 
but intact in IL-23R-deficient patient cells (Fig. 3B). By contrast, “Th17” differentiation in 
vitro in the presence of IL-23, as assessed by monitoring IL-17F production, was 
maintained in IL-12Rβ2-deficient cells, but abolished in naïve CD4+ T cells from IL-23R- 
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and IL-12Rβ1-deficient patients (Fig. 3B). Following “Th2” differentiation in vitro, which 
occurs in the presence of IL-4, cells of all genotypes produced similar amounts of IL-10 
(Fig. 3B). Collectively, these data suggest that the cytokine-dependent in vitro 
differentiation of naïve CD4+ T cells into “Th1” and “Th17” cells is affected by IL-12Rβ2 
deficiency and IL-23R deficiency, respectively, consistent with previous findings (13). We 
probed genotype-dependent effects on the generation of cytokine-producing CD4+ T cells 
in vivo further, by purifying naïve (CD45RA+CCR7+) and memory (CD45RA–) CD4+ T 
cells from healthy donors, IL-12Rβ2-, IL23R- or IL-12Rβ1-deficient patients and culturing 
them with polyclonal TCR-activating ligands (Th0 conditions) (36). As expected, IL-
12Rβ1- and IL23R-deficient cell cultures displayed only low levels of IL-17A and IL-17F 
production (Fig. 3C). Similar amounts of IL-10 were again produced by all cells tested. 
Surprisingly, the production of IFN-g, TNF, and IL-2 by memory CD4+ T cells was reduced 
not only by IL-12Rβ1 or IL-12Rβ2 deficiency, but also by IL-23R deficiency, possibly due 
to T cell-intrinsic functional defects or to the low frequency of Th1 and/or Th1* cells in 
the three groups of patients.  
Mycobacterium-specific IFN-g production is compromised in Th cells 
We assessed the potential effects of deficiencies of IL-12Rβ1, IL-12Rβ2, or IL-23R 
on the induction of Mycobacterium-specific CD4+ T-cell responses in vivo, by analyzing 
memory CD4+ T cells from healthy controls and patients of each genotype (37). Both BCG-
vaccinated and -unvaccinated individuals have been shown to robustly produce IFN-g in 
response to BCG (38) and mycobacteria-derived antigens (39). Multiple T-cell lines were 
generated from sorted CD4+CD45RA–CCR6– cells (containing Th1 and Th2 cells and 
known to be enriched in viral antigen-reactive T cells) and CD4+CD45RA–CCR6+ cells 
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(containing Th1* and Th17 cells known to be enriched in bacterial and fungal antigen-
reactive T cells, respectively) separately (40). Following polyclonal stimulation, both 
CCR6+ and CCR6– T cells produced IFN-g in similar amounts for healthy controls and all 
patients (Fig. S5A). By contrast, IL-17A and IL-22 were produced mostly by CCR6+ cells 
for healthy controls and an IL-12Rβ2-deficient patient, but not for IL-12Rβ1- and IL-23R-
deficient patients (Fig. S5A), consistent with the notion that IL-23 is an important inducer 
of the production of IL-17A and IL-22 by CD4+ T cells (41). In the same experiment, the 
production of IL-4 was not affected by any of the mutations tested (Fig. S5A). All T-cell 
lines were then screened in vitro for recall responses to influenza virus, respiratory 
syncytial virus (RSV), BCG, and Mycobacterium tuberculosis (MTB). Several T-cell lines 
from both healthy donors and patients proliferated in response to the antigens tested (Fig. 
S5B). As expected, the frequency of influenza- and RSV-reactive cells was higher in 
CCR6- T-cell lines, whereas the frequency of BCG- and MTB-reactive cells was higher in 
CCR6+ T-cell lines. (Fig. S5B-C). No major differences in the frequency of precursor cells 
specific for the tested antigens (Fig. S5C) were observed, but genotype-dependent defects 
were observed in the production of cytokines by proliferating T cells. The production of 
IFN-g, but not of IL-4, by influenza virus- or RSV-reactive CCR6– T cells was impaired in 
IL-12Rb2- and IL-12Rb1-deficient patients, but not in IL-23R-deficient patients (Fig. 
S5D). Interestingly, the levels of IFN-g production by BCG- and MTB-responding CCR6+ 
T cells were low in IL-12Rβ1-, IL-12Rβ2-, and IL-23R-deficient patients (Fig. 4A, left 
panels). IL-17A was produced by only a few healthy donor CCR6+ T cells in response to 
BCG and MTB, precluding comparisons between genotypes (Fig. 4A). In the same cells, 
IL-22 production was low in IL-12b1- and IL-23R-deficient patients, but not in IL-12Rb2-
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deficient patients (Fig 4A), providing further evidence of a functional IL-23R deficiency. 
However, the role of human IL-22 in immunity to infection remains undetermined. 
Interestingly, CD4+ T cells from Il23a-/- mice showed severely defective IL-17 and IL-22 
production, mildly reduced IFN-g production, and increased mycobacterial growth, when 
compared with WT mice following M. tuberculosis infection (42). Yet, Il17ra-/- and Il22-
/- mice did not differ from WT mice in their control of M. tuberculosis growth (42), unlike 
Ifng-/- mice (43) suggesting that IL-23-dependent IFN-g production is involved in this 
setting. Other studies have shown that IL-23 augments local IFN-g production in the lung 
and limits pulmonary M. tuberculosis replication in mice (44). Overall, these data indicate 
that, in the absence of either IL-12 or IL-23 signaling, Mycobacterium-specific IFN-g 
production is compromised in CCR6+ memory CD4+ Th1* cells, a cellular phenotype 
common to inherited ROR-g/ROR-gT (36) and SPPL2A deficiencies (Kong X-F., 
Martinez-Barricarte R., Nature Immunology, in press). 
 
 
Lymphocyte subsets respond differently to IL-12 and IL-23 
However, the mycobacterial disease in the patients studied cannot be entirely 
dependent on impaired effector functions of CD4+ T cells alone, as patients with HLA-II 
deficiency due to mutations of CIITA, RFXANK, RFXAP, or RFX5, with very low 
frequencies of functional CD4+ ab T cells, are not prone to clinical disease caused by 
weakly virulent mycobacteria (45). Indeed, BCG or environmental mycobacterial disease 
of genetic origin in patients without isolated or syndromic MSMD, has been documented 
only in patients with severe combined immunodeficiency (SCID), who lack all types of 
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endogenous T cells (46). An additional lack of NK cells in SCID patients seems to underlie 
more frequent and severe forms of mycobacterial disease (unpublished), although isolated 
NK deficiency does not confer a predisposition to mycobacterial disease (47–49). We 
therefore assessed mRNA levels for IL12RB1, IL12RB2, and IL23R in various leukocyte 
subsets, and assessed the consequences of IL-12 and IL-23 signaling in each of these cell 
types. Human IL12RB1 mRNA production has been reported in many types of human 
leukocytes, the lowest levels being reported in B cells and monocytes and the highest levels 
in NK cells (50). IL12RB2 and IL23R display a high degree of sequence identity and 
probably arose through gene duplication (12), but they nevertheless have different patterns 
of expression, with IL12RB2 mRNA levels highest in γδ T cells and NK cells, whereas 
IL23R mRNA levels are highest in γδ T cells and only moderate in CD4+ and CD8+ ab T 
cells (50). We confirmed these findings (Fig. S6A), and stimulated purified B, CD4+ ab T, 
CD8+ ab T, γδ T, and NK cells from healthy donors with IL-12 or IL-23 for 6 h, before 
assessing the genome-wide transcriptional consequences by mRNA microarray analysis. 
Cytokine-specific and cell type-specific patterns were observed (Tables S2 and S3). 
Strikingly, IFNG transcripts were the most consistently induced across cell types and 
stimuli (Fig. 4C-D). This result was validated by qPCR (Fig 4E) and ELISA for IFN-g on 
cell culture supernatants (Fig. 4F). We expanded this study to include MAIT, NKT cells, 
and ILCs, all of which have been reported to be potent IFN-γ producers (reviewed in (51, 
52)). MAIT and NKT cells clearly responded to each cytokine by producing IFN-γ, but 
they responded more strongly to IL-23 (Fig. 4G-H). ILC1 and ILC2 isolated from 
peripheral blood responded to IL-12, but not IL-23, by producing IFN-γ (Fig. 4H). ILC3 
isolated from tonsillar tissue clearly responded to IL-23 and IL-12 by producing IFN-γ 
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(Fig. 4I). Finally, the stimulation of PBMCs from healthy donors or IL-12Rb1-deficient 
patients with M. bovis BCG together with IL-12 or IL-23 revealed that IL-12 strongly 
potentiated the IFN-γ response to BCG, but that IL-23 also increased IFN-γ production, 
albeit to a lesser extent (Fig. S6B-D).  
 
Discussion 
 Collectively, these data shed light on the respective contributions of IL-12 and IL-
23 to human immunity to Mycobacterium and Candida, through the discovery and 
characterization of AR complete IL-12Rb2 and IL-23R deficiencies in two multiplex 
MSMD kindreds without CMC. The surprising absence of CMC in IL-23R-deficient P4 
and P5, as in most patients with complete IL-12Rb1 deficiency, may be due to the 
incomplete penetrance of IL-23 deficiency for poor IL-17A/IL-17F production, or the 
incomplete penetrance of low levels of IL-17 production for CMC, or both. Indeed, all 
known forms of isolated or syndromic CMC disrupt IL-17A/F immunity (16, 18–22). 
These data also reveal the specific transcriptional consequences of IL-12 vs. IL-23 
signaling in human B, CD4+ ab T, CD8+ ab T, gd T, MAIT, NKT, NK cells and ILCs, 
with a notable convergence on IFN-γ induction (Table S4). Clinically, these results add 
IL12RB2 and IL23R to the list of 11 other genes (IFNGR1, IFNGR2, STAT1, IL12B, 
IL12RB1, NEMO, CYBB, IRF8, ISG15, TYK2, SPPL2A) mutated in MSMD patients, the 
products of which are all involved in IFN-γ-mediated immunity (4, 5, 36). Importantly, 
patients with deleterious mutations in IL17F, IL17RA, IL17RA, or ACT1 have CMC 
without mycobacterial disease immunity (16, 18–22). Ouresults therefore reveal that both 
IL-12- and IL-23-dependent signaling pathways play critical roles in human anti-
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mycobacterial immunity, via the induction of IFN-g. Indeed, our findings show that human 
IL-12 and IL-23 are partly, but not totally redundant with each other, for IFN-g-dependent 
anti-mycobacterial immunity. These findings in natural conditions in humans corroborate 
and extend previous experiments performed in mice (42).  
  IL-12- and IL-23-dependent induction of IFN-g may occur either within the same 
cell type, or differentially across different cell types, and IL-23 may provoke IFN-g by 
direct or indirect means (which may include IL-17- and IL-22-dependent and -independent 
processes).  The absence of response to both these molecules, as in patients with complete 
IL-12Rb1 deficiency, underlies MSMD with incomplete but high penetrance, reaching an 
estimated 65% by five years of age and 80% in adults (4). It was not possible to calculate 
the penetrance of IL-12Rb2 and IL-23 deficiencies, but the data from our population and 
family genetic studies strongly suggest that penetrance is much lower in both these 
deficiencies, accounting for the diagnosis of IL-12Rb1 deficiency in a hundred times as 
many kindreds to date. This notion is strongly supported by our accompanying report that 
as many as 1/1,000 Europeans homozygous for TYK2 P1104A have normal responses to 
IL-12, and impaired responses to IL-23, rendering them vulnerable to tuberculosis and, 
more rarely, to MSMD (Boisson-Dupuis S, Ramirez-Alejo N., et al.). The primary, 
essential function of both IL-12 and IL-23 in humans is to induce IFN-g and control 
mycobacteria and other intramacrophagic pathogens, perhaps due to the duplication of the 
loci encoding both these cytokines and their receptors. The contribution of IL-23 to IL-17 
anti-fungal immunity is more modest and may be more recent in terms of evolution, as 
both the IL-23R-deficient patients described here, and most IL-12Rβ1-deficient patients 
described to date are not susceptible to Candida.  
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Figure legends 
Figure 1: Identification of homozygous complete loss-of-function IL-12Rb2 Q138X 
and IL-23R C115Y mutations in families with MSMD.  
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A, B) Pedigrees of the two kindreds studied in this report. The gene and mutation are 
indicated under the kindred name. Solid black symbols indicate patients with MSMD and 
solid gray symbols indicate cases of primary tuberculosis during childhood. Symbols 
linked with a double line indicate consanguinity. The genotype is indicated under each 
symbol, with M corresponding to the mutation found in each kindred. Arrows indicate the 
index case in each family. C, D) Schematic representation of IL-12Rβ2 (C) and IL-23R 
(D). Rectangles represent individual exons of the gene, with the exon numbers indicated 
within the rectangle. In each case, the N terminal portion of the protein is the extracellular 
domain, and gray shaded areas represent the transmembrane domain. The mutations 
studied here are indicated below each protein, in the corresponding exons. E) HEK293T 
cells were either non-transfected (NT) or transfected with an empty vector (EV), a vector 
containing the C-terminal V5-tagged WT or Q138X mutant versions IL12RB2. Western 
blotting was performed with antibodies against the V5 tag, or GAPDH as a loading control. 
F) LCL-BSTAT4 cells were either non-transduced (NT), or transduced with retroviruses 
generated with an empty vector (EV) or with vectors containing the WT or C115Y mutant 
versions of IL23R. Cells were either left untreated, or treated with kifunensine to inhibit N-
glycosylation. Western blotting was performed with antibodies against the V5 tag, or 
GAPDH as a loading control. G) LCL-BSTAT4 cells from (F) were stained with an anti-IL-
23R biotinylated primary antibody, then with avidin-PE, and the mean fluorescence 
intensity (MFI) for the PE signal was quantified by flow cytometry. H) LCL-BSTAT4 cells 
were either left non-transduced (NT), or were transduced with retroviruses generated with 
an empty vector (EV) or vectors containing V5-tagged WT or Q138X mutant versions of 
IL12RB2, or WT or C115Y versions of IL23R. The cells were left unstimulated, or were 
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stimulated with IL-12 or IFN-a. Cell lysates were prepared, and western blotting was 
performed with antibodies against pSTAT4, total STAT4, and GAPDH. I) LCL-BSTAT4 
cells from (H) were left unstimulated, or were stimulated with IL-23 or IFN-a as a positive 
control. Cell lysates were prepared, and western blotting was performed with antibodies 
against pSTAT3, total STAT3, and GAPDH. J) HVS-T cells from a healthy control (C+), 
an IL-12Rb1-/- patient or P1 (IL-12Rb2 Q138X) were not transduced (NT), or were 
transduced with a retrovirus generated with an empty vector (EV) or a WT allele of 
IL12RB2 and then stimulated with IL-12 or IFN-α. Western blotting was performed as 
described in (H). K) EBV-B cells from a healthy control (C+), an IL-12Rb1-/- patient or P4 
(IL-23R C115Y) were not transduced (NT), or were transduced with a retrovirus generated 
with an empty vector (EV) or a WT allele of IL23R and then stimulated with IL-23 or IFN-
α. Western blotting was performed as described in (I). 
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Figure 2: IL12RB2 and IL23R are evolving under weak purifying selection, and 
homozygous complete loss-of-function mutations of these genes occur rarely in the 
general population.  
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A, B) Graphic representation of all genes of the human genome according to the log10 of 
their (A) neutrality index (NI) or (B) gene damage index (GDI, (31)). IL12RB2 (blue), 
IL23R (red), and IL12RB1 (grey) are each indicated by a dashed vertical line. C, D) All 
homozygous variations found in gnomAD for IL12RB2 (C) and IL23R (D) are plotted 
according to their CADD score (y-axis) and minor allele frequency (MAF, x-axis). The 
dashed line indicates the mutation significance cutoff (MSC, (26)) for each gene. E) LCL-
BSTAT4 cells were left non-transduced (NT), or were transduced with retroviruses generated 
with an empty vector (EV) or vectors containing V5-tagged WT or mutant versions of 
IL12RB2, including the 16 mutations indicated. These IL12RB2 mutations are present in at 
least one individual in the gnomAD database. Cells were left unstimulated, or were 
stimulated with IL-12 or IFN-a. Cell lysates were prepared, and western blotting was 
performed with antibodies against pSTAT4, total STAT4, and GAPDH. F) LCL-BSTAT4 
cells were left non-transduced (NT), or were transduced with retroviruses generated with 
an empty vector (EV) or vectors containing V5-tagged WT or mutant versions of IL23R, 
for the 14 mutations indicated. With the exception of the C115Y mutation found in kindred 
B, these IL23R mutations are each present in at least one individual in the gnomAD 
database. Cells were left unstimulated, or were stimulated with IL-23 or IFN-a. Cell lysates 
were prepared, and western blotting was performed with antibodies against pSTAT3, total 
STAT3, and GAPDH. 
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Figure 3: Frequencies and responses of CD4+ T cells from IL-12Rb1-, IL-12Rb2- and 
IL-23R-deficient individuals to polyclonal stimuli or Th-polarizing cytokines.   
 
A) On the left, frequencies of naïve (CCR7+CD45RA+), central memory (CCR7+CD45RA–
), effector memory (CCR7–CD45RA–) and TEMRA (CCR7–CD45RA+) CD4+CD3+ T cells 
were measured in healthy controls (n=16), IL-12Rβ2-Q138X patients (n=2, one measured 
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twice), one IL-23R-C115Y patient (technical triplicates) and IL-12Rb1-/- patients (n=5). 
The values shown are the percentage of total CD4+ T cells. On the right, frequencies of 
four subsets of CD4+ memory T cells (CD3+CD45RA–): Th1 (CCR6–CCR4–CXCR3+), 
Th1* (CCR6+CCR4–CXCR3+), Th17 (CCR6+CCR4+CXCR3–) and Th2 (CCR6–
CCR4+CXCR3–) were measured in the same individuals as in the left panel. Error bars 
indicate the SEM. P values for the comparison of healthy controls with IL-12Rβ1-deficient 
patients in Mann-Whitney U-tests are shown. Formal statistical comparisons including IL-
12Rβ2-Q138X and IL-23R-C115Y patients were not appropriate, due to the extremely 
small number of individuals (2 and 1, respectively).  B) Naïve CD4+ T cells from healthy 
controls, two IL-12Rβ2-Q138X patients (P1 and P2), one IL-23R-C115Y patient (P4) and 
four IL-12Rβ1-deficient patients were either left unpolarized (Th0) or were polarized under 
Th1 conditions (TAE+IL-12), Th17 conditions (TAE+IL-1/IL-6/IL-21/IL-23/TGF-b), or 
Th2 conditions (TAE+IL-4). The production of IFN-γ, IL-17F and IL-10 was measured 
with cytometric bead arrays, in cell culture supernatants, after 5 days. C) Naïve and 
memory CD4+ T cells from healthy controls, two IL-12Rβ2-Q138X (P1 and P2), one IL-
23R-C115Y (P4) and four IL-12Rβ1-deficient patients were stimulated with TAE beads, 
and cytokine production was measured 5 days later. Data for the production of IFN-γ, TNF 
and IL-2 are shown in the upper panels and for IL-17A, IL-17F and IL-10 in the lower 
panels.  
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Figure 4: Specific defects in the IL-12- and IL-23-dependent generation of an IFN-g 
immune response in patients with novel homozygous mutations of IL12RB2 or IL23R.  
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A, B) Multiple CCR6+ or CCR6– memory CD4+ T-cell lines were generated by the 
polyclonal stimulation of sorted peripheral blood subsets from healthy controls (n=4), one 
IL-12Rβ2-Q138X patient, one IL-23R-C115Y patient, and three IL-12Rβ1-deficient 
patients. Lines were screened for reactivity with peptide pools covering antigens from BCG 
(upper panel) and MTB (lower panel). BCG- and MTB-reactive CD4+CCR6+ T-cell lines 
from each individual were selected and the cytokines accumulating in the culture 
supernatant were determined with a Luminex machine. Each dot on the graph corresponds 
to a value for a single antigen-reactive T-cell line. CCR6+ T-cell lines are shown as closed 
circles, and CCR6- cell lines are shown as open circles. C, D) Microarray heat map of 
isolated B, CD4+ T, CD8+ T, γδ+ T and NK cells stimulated with IL-12 (C) or IL-23 (D) 
for 6 h. The data shown are the fold-induction relative to non-stimulated (n.s.) cells. The 
most commonly upregulated gene, IFNG, is highlighted in the lower right corner of each 
heat map. E) IFNG induction by isolated B, CD4+ T, CD8+ T, γδT, and NK cells from 5 
healthy controls, upon stimulation with IL-12 or IL-23 for 6 h, was assessed by qPCR, and 
the data were normalized relative to n.s. cells. F) IFN-γ levels in the supernatants from the 
cells used in (E) were analyzed by ELISA and represented as a fold-change, relative to n.s. 
cells. G, H) Sorted MAIT cells (G) or NKT cells (H) (>95% pure) were left unstimulated, 
or stimulated with rhIL-12 (20 ng/mL) or rhIL-23 (100 ng/mL) for 6 h. Cell culture 
supernatants were harvested and used for IFN-γ determination in a multiplex cytokine 
assay. I) NK cells, ILC1, or ILC2 were sorted, by FACS, from blood samples from healthy 
donors and cultured in the presence of the indicated cytokines for 24 h. Total ILCs were 
gated on viable CD45+Lin– (CD3–CD4–CD5–TCRab–TCRgd–CD14–CD19–) CD7+ cells. 
NK cells were identified as CD56bright and CD56dim, ILC2 as CD56–CD127+CRTh2+ and 
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ILC1 as CD56–CD127+CD117–CRTh2–. IFN-γ levels were determined by intracellular 
staining. ILC3 were sorted by FACS from the tonsillar tissues of healthy donors, by gating 
on viable CD45+ Lin–CD7+CD117+NKp44+ cells. ILC3 were cultured for 4 days in the 
presence of the indicated cytokines, and IFN-γ was then determined by intracellular 
staining.  
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Case Reports 
Kindred A: P1 was born in 2008 to first-cousin consanguineous parents from Turkey (Fig. 
1A, III.2). She was vaccinated with BCG at the age of three months and presented left 
axillary lymphadenitis (5 cm x 5 cm) at 17 months of age. A tuberculin skin test was 
strongly positive (PPD = 20x20 mm). Initial hemoglobin concentration was 11.8 g/dl, 
WBC was 13,000/mm3, absolute neutrophil count was 7,000/mm3, and absolute 
lymphocyte count was 4,700/mm3. Tests for HIV antibody were negative. Serum 
immunoglobulin levels were normal. Peripheral blood lymphocyte subsets and in vitro T-
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cell functions were normal. Neutrophil function was normal in terms of respiratory burst, 
tested in the DHR assay (upon PMA activation). CD212 (IL-12Rb1) expression was 
normal (CD212: 93% of leukocytes). Chest X-ray findings were normal. Pathology 
examinations of the lymph node capsule biopsy specimen revealed caseating 
granulomatous inflammation. Ziehl-Neelsen staining for acid-fast bacilli (AFB) detected 
such bacilli within histiocytes. M. tuberculosis infection could not be confirmed by 
diagnostic PCR and the Mycobacterium bovis-BCG vaccine was suspected. Ziehl-Neelsen 
staining for AFB was negative for a gastric aspirate sample. The patient was diagnosed 
with BCG-osis and treated with isoniazid, rifampin, ethambutol and clarithromycin. After 
two months, ethambutol and clarithromycin treatments were stopped, and isoniazid and 
rifampin were continued for six months. The patient made a full recovery and has never 
had Salmonella or Candida infections.  
P2 was born, in 1989, to first-cousin consanguineous parents (Fig. 1A, II.3). P2 had 
pulmonary tuberculosis at the age of five years, for which he received anti-TB treatment 
(details not available) and recovered. He has never had Salmonella or fungal infections. 
His family history contains no other remarkable elements and P2 is healthy without 
treatment.  
P3 was born in 1979 and is asymptomatic. P2 and P3 are the uncles of P1. 
Kindred B: P4 was born in 1994, to consanguineous parents from Iran (Fig. 1B, II.1). P4 
was vaccinated with BCG in early infancy and developed BCG-adenitis with pus discharge, 
which persisted for one year and then spontaneously resolved. She is now well, with no 
treatment. Her younger brother, P5, was born in 2006 (Fig. 1B, II.5). He was also 
vaccinated with BCG in early infancy, after which he developed axillary lymphadenopathy 
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that did not resolve. At the age of five years, he was admitted to hospital for 
hepatosplenomegaly and mediastinal lymphadenopathy. He was treated with an 
antimycobacterial drug regimen, including isoniazid, rifampicin, ethambutol, ofloxacillin, 
clarythromysin, cycloserine, and dapsone, for 1.5 years. He was also treated with 
exogenous IFN-g therapy. PPD testing at the age of seven years was negative. From the 
age of seven years, P5’s infection progressed despite treatment, and he died of disseminated 
BCG disease at the age of eight years. 
 
 
Materials and Methods 
Genome-wide linkage (GWL) analysis: GWL analysis was performed as previously 
described (53), with minor modifications. For Kindred A, P1 was genotyped with the 
Affymetrix Genome-Wide Human SNP array 6.0, and six other individuals (P2, P3, II.5, 
II.6, III.1, III.3) were genotyped with the Affymetrix Genome-Wide Human SNP array 
250K. For Kindred B, all seven individuals shown in the pedigree (Fig. 1B) were genotyped 
with the Affymetrix Genome-Wide Human SNP array 250K. Genotype was called with the 
Affymetrix Power Tools software package 
(http://www.affymetrix.com/estore/partners_programs/programs/developer/tools/powerto
ols.affx). SNPs presenting more than one Mendelian inconsistency were discarded and the 
remaining SNPs were filtered with population-based filters (54). For Kindred A, we used 
164,052 SNP markers for linkage analysis, assuming AR inheritance with 75% penetrance, 
and a deleterious allele frequency of 10-4. For Kindred B, we used 162,563 SNP markers 
for linkage analysis, assuming AR inheritance with 75% penetrance, and a deleterious 
allele frequency of 10-4. The penetrance estimate was based on the known clinical 
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penetrance of IL-12Rb1 deficiency (6, 7). Parametric multipoint linkage analysis was 
carried out independently for each kindred with the Merlin program (55), considering the 
founders to be second-degree relatives. The family founders and HapMap CEU trios were 
used to estimate allele frequencies and to define linkage clusters, with an r2 threshold of 
0.4.  
 
Principal component analysis (PCA): PCA was conducted using whole exome sequencing 
(WES) data of 3752 individuals of diverse ethnic origins from our in-house exome database 
and 2504 unaffected individuals of the 1000 Genomes Project as reference individuals, as 
described (24). The analysis was restricted to variants covered by the exome capture 
Agilent’s SureSelect V1 with a MAF greater than 5%. The principal components were 
obtained using the software PLINK (54). 
 
Whole-exome sequencing (WES): Genomic DNA was prepared from blood samples from 
P1, P2, P3, P4 and P5. The DNA was sheared with a Covaris S2 Ultrasonicator (Covaris), 
and an adapter-ligated library was prepared with the Paired-End Sample Prep kit V1 
(Illumina). Exome capture was performed with the Aligent SureSelect Human Exome kit 
(71 Mb version), according to the manufacturer’s instructions. Exome sequencing was 
performed by the New York Genome Center, on an Illumina HiSeq 2500 machine. The 
reads were aligned to the human reference genome with BWA (56), then recalibrated and 
annotated with GATK (57), PICARD (http://picard.sourceforge.net/) and ANNOVAR 
(58). Substitution calls were made with GATK UnifiedGenotyper, whereas indel calls were 
made with SomaticIndelDetectorV2. All calls with a read coverage <2x and a Phred-scaled 
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SNP quality of <20 were filtered out. The variants were further filtered and investigated 
with our in-house online server (59). All IL12RB2 and IL23R mutations identified by WES 
were confirmed by Sanger sequencing. Familial segregation analysis was performed in 
both families, when the necessary material was available. 
 
Population genetic analyses: We estimated the strength of the purifying selection acting on 
IL12RB1, IL12RB2 and IL23R in humans, using an approach based on polymorphism and 
divergence data from synonymous and nonsynonymous sites within genes (i.e., the 
McDonald-Kreitman table). This method, known as SnIPRE (29), uses a generalized linear 
mixed model to model genome-wide variability for categories of mutations and estimates 
two key population genetic parameters for each gene: γ, the population selection 
coefficient, and f, the proportion of nonsynonymous mutations that are non-lethal. We 
focused our investigation on the f parameter, which quantifies the strength of purifying 
selection acting on human genes (i.e., the removal of deleterious alleles from the general 
population). The f parameter thus varies from 0 (all nonsynonymous mutations in the gene 
are lethal) to 1 (all nonsynonymous mutations in the gene are non-lethal). We first retrieved 
the alignment of the hg19 human genome and the PanTro3 chimp genome from UCSC 
Genome Browser. All differences between the two species were annotated functionally by 
snpEff (60), using the GRCh37.65 build. We retrieved all human CDS >20 bp long and 
considered, for each gene, the longest transcript available. We deduced the proportion of 
synonymous and non-synonymous sites in the 22,616 coding DNA sequences (CDS) 
obtained, accounting for gaps in human-chimp alignments. We then retrieved all 
polymorphisms identified in the WES data of phase 1 of the 1,000 Genomes Project (30). 
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We analyzed SNPs that were annotated as non-synonymous or synonymous, outside of 
gaps in the human-chimp alignment and polymorphic in at least one human population. 
We also removed from positions divergent between humans and chimps those that were 
actually polymorphic in humans or chimps, using the dbSNP136 chimp database. We 
finally obtained the number of divergent and polymorphic synonymous and 
nonsynonymous mutations, and the proportion of synonymous and nonsynonymous sites, 
in a total of 18,969 genes. SnIPRE was then used to estimate the f parameter, and genes of 
interest were ranked on the basis of f estimations.  
 
Cell culture: The B-lymphoblastoid cell line (LCL-B) endogenously negative for IL-12Rb2 
and IL-23R expression, positive for IL-12Rb1, STAT3, and engineered to express STAT4-
iresGFP in a stable manner used, referred to hereafter as LCL-BSTAT4, has been described 
elsewhere (27). T-cell lines were generated by infecting peripheral blood mononuclear 
cells (PBMCs) from healthy controls or patients with Herpesvirus saimiri, as previously 
described (61). Herpesvirus saimiri-immortalized T (HSV-T) cells were cultured with a 
1:1 mixture (by volume) of RPMI and Panserin 401 (Panbiotech), supplemented with 10% 
fetal bovine serum (FBS), 350 µg/ml glutamine, 100 c/ml gentamycin, and 10 U/ml hIL-2 
(Roche). Phoenix-A packaging cells (ATCC) were cultured in IMDM medium (Gibco) 
supplemented with 10% FCS. B-LCLSTAT4, Epstein-Barr virus-transformed B cells (EBV-
B cells), and PBMCs were cultured in RPMI supplemented with 10% FCS. In other 
experiments, 300,000 HEK293T cells/well were seeded in 6-well plates. The next day, 5 
µg of pcDNA3.1-empty vector or pcDNA3.1 containing a C-terminally V5-tagged WT or 
Q138X IL12RB2 were transfected in the presence of Lipofectamine reagent (Invitrogen), 
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per manufacturer’s instructions. After 48 h, whole cell lysates (100 µg protein per lane) 
were subjected to SDS-PAGE electrophoresis in a 10% acrylamide/bisacrylamide gel, and 
the resulting bands were transferred to a PVDF membrane (Immobilon-P, Millipore). The 
membrane was then probed with antibodies directed against V5 (460708: Invitrogen), and 
GAPDH (G-9: Santa Cruz). 
  
Production of retroviral particles: Plasmids containing the WT human IL12RB2 (Origene 
#SC119132) or IL23R (Origene #RG211477) ORFs were obtained, and different alleles 
were generated by site-directed mutagenesis, with specific primers and the PFU II Hotstart 
PCR Master Mix (Agilent Technologies), according to the manufacturer’s instructions. 
These ORFs were introduced into the pLZRS-IRES-ΔNGFR vector and used to generate 
retroviral particles, as previously described (62). Briefly, 10 µg of the retroviral vector 
pLZRS-IRES-ΔNGFR (empty vector), or the same vector backbone containing one of the 
insert sequences WT IL12RB2-V5, WT IL23R-V5, or one of the variants functionally 
characterized in this report, was used to transfect Phoenix-A packaging cells (ATCC) in 
the presence of the X-treme Gene 9 transfection reagent (Roche), according to the 
manufacturer’s protocol. The ΔNGFR ORF encodes a truncated nerve growth factor 
receptor (NGFR, also known as CD271) protein that cannot transduce signal, which serves 
as a cell surface tag in this system. Transfected Phoenix-A cells were cultured with 2 µg/ml 
puromycin (Gibco) until all cells expressed ΔNGFR on their surface, as shown by flow 
cytometry with a PE-conjugated mouse anti-human NGFR antibody (BD Pharmingen). 
Phoenix-A packaging cells were cultured for another 24 h in the presence 2 µg/ml 
puromycin. The medium was then changed and the puromycin was removed. The virus-
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containing culture supernatant was collected 24 h later. Retroviruses were concentrated 
from the culture supernatant with Retro-X Concentrator (Clontech), according to the 
manufacturer’s protocol, and stored at -80°C until use. 
 
Retroviral transduction: HVS-T cells, EBV-B cells, or LCL-BSTAT cells were transduced 
with retroviral particles by spinoculation (62). Briefly, six-well non-tissue culture treated 
plates were coated by incubation for 24 h with 100 ng/ml of RetroNectin (Takara) diluted 
in PBS. The next day, the wells were washed with PBS and the viral supernatants were 
thawed and added to the empty wells, and the volume in each well was made up to 2 ml 
with medium. Plates were centrifuged at 800 x g for 30 min and 106 cells were added to 
each well. The plates were centrifuged for 5 min at 300 x g and incubated at 37ºC for 5 
days before the assessment of transduction efficiency. Transduced cells were purified by 
MACS, using magnetic bead-conjugated anti-NGFR antibody (Miltenyi Biotec), according 
to the manufacturer’s protocol, and purity was confirmed, by flow cytometry, to be >95%.  
 
Western blotting to assess the activation of STAT3 and STAT4: LCL-BSTAT4 cells that were 
non-transduced, or retrovirally transduced and stably expressing the desired IL-12Rb2 or 
IL-23R proteins, were left unstimulated, or were stimulated with rhIL-12 (20 ng/ml; R&D 
Systems), rhIL-23 (100 ng/ml; R&D Systems) or rhIFN-a2b (105 units/mL, Intron-AÒ, 
Schering) for 30 min. The culture medium was removed, and the cells were washed with 
ice-cold PBS, and lysed in RIPA buffer (50 mM TRIS pH8, 1 mM EDTA, 150 mM NaCl, 
0.5% sodium deoxycholate, 1% NP40, 0.1% SDS) supplemented with 100 mM sodium 
orthovanadate and Complete Mini protease inhibitor cocktail (Roche). Whole lysates (100 
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µg protein per lane) were subjected to SDS-PAGE electrophoresis in a 10% 
acrylamide/bisacrylamide gel, and the resulting bands were transferred to a PVDF 
membrane (Immobilon-P, Millipore). The membrane was then probed with antibodies 
directed against V5 (460708: Invitrogen), phospho-STAT3 Tyr705 (9145S: Cell 
Signaling), STAT3 (9139S: Cell Signaling), phospho-STAT4 Tyr693 (AF4319: R&D 
systems), STAT4 (C46B10: Cell Signaling), phospho-TYK2 Tyr1054/1055 (9321S: Cell 
Signaling), TYK2 (14193S: Cell Signaling), phospho-JAK2 Tyr1007/1008 (C80C3: Cell 
Signaling), JAK2 (D2E12 XP: Cell Signaling) and GAPDH (G-9: Santa Cruz). 
 
Western blotting to assess IL-23R N-glycosylation: Protein lysates were prepared as 
described above, from LCL-BSTAT4 cells that were non-transduced, or retrovirally 
transduced to express the WT or C115Y IL-23R V5-tagged proteins. Chemical inhibitors 
of N-glycosylation were used, as previously described (28, 63). Briefly, cells were left 
untreated or were treated with 166 mM kifunensine (Toronto Research Chemicals). After 
48 hours, cell lysates were prepared as described above. Protein samples were then left 
untreated or digested overnight at 37°C with endoglycosidase-H (EndoH; Biolabs) or 
peptide N-glycoside-F (PNGaseF; Biolabs) in the appropriate buffer. Immunoblotting was 
performed with antibodies directed against V5 (460708: Invitrogen), and GAPDH (G-9: 
Santa Cruz).  
 
CXCL10 ELISA: LCL-BSTAT4 cells that were non-transduced, or retrovirally transduced 
and stably expressing the desired IL-12Rb2 or IL-23R proteins, were left unstimulated, or 
were stimulated with rhIL-12 (20 ng/ml; R&D Systems) or rhIL-23 (100 ng/ml; R&D 
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Systems) for 24 h. Cell-free supernatants were collected, and used for CXCL10 
quantification by ELISA (Biolegend #439904), according to the manufacturer’s protocol. 
Results are expressed as the fold-change difference between IL12- or IL-23-stimulated and 
non-stimulated cells, for each cell type.  
 
Genetic rescue experiments: HVS-T cells were generated from the PBMCs of P1, and were 
left non-transduced, or transduced with retroviral particles produced with pLZRS-IRES-
ΔNGFR (empty vector), or with a vector consisting of the same backbone plus WT 
IL12RB2-V5, as described above. EBV-B cells were generated from the PBMCs of P4, as 
described above. Cells were left non-transduced, were transduced with retroviral particles 
produced with pLZRS-IRES-ΔNGFR (empty vector), or with a vector containing the same 
backbone plus WT IL23R-V5, as described above.   
 
IL12RB2 K649N mRNA splicing experiments: PBMCs were obtained from two healthy 
controls and a patient with a heterozygous IL12RB2 mutation c.1947G>C, located in the 
first nucleotide of exon 15 and potentially causing both the K649N substitution and 
alternative splicing. Phytohemagglutinin (PHA)-blasts were generated by stimulating 2 x 
106 PBMCs with 5 µg/ml PHA for 72 h. Total RNA was extracted from PHA-blasts or 
HVS-transformed T cells with TRIzol (Invitrogen), according to the manufacturer’s 
protocol. We generated cDNA from 5 µg of total RNA, with the SuperScript First-Strand 
III Synthesis System for RT-PCR (Invitrogen). PCR was performed with primers binding 
between exons 12 and 15 of IL12RB2 (5’-GCC CCG AGT GAC ATA TGT CA-3’ and 5’-
CTT TTT CCC TTT GTG GCC AG-3’). The PCR products were inserted into the pGEM-
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T Easy vector (Promega, Madison, WI) and sequenced individually.  
 
Ex vivo naïve and effector/memory CD4+ T-cell stimulation: CD4+ T cells were isolated as 
previously described (64). Briefly, cells were labeled with anti-CD4, anti-CD45RA, and 
anti-CCR7 antibodies, and naïve (defined as CD45RA+CCR7+CD4+) or effector/memory 
(defined as CD45RA–CCR7–CD4+) T cells were isolated (>98% purity) on a FACS Aria 
machine (BD Biosciences). Purified naïve or effector/memory CD4+ cells were cultured 
with T-cell activation and expansion (TAE) beads (anti-CD2/CD3/CD28; Miltenyi Biotec) 
for 5 days, and culture supernatants were then used to assess the secretion of the cytokine 
indicated, by ELISA (IL-22) or in a cytometric bead array (all other cytokines). 
 
In vitro differentiation of naïve CD4+ T cells: Naïve CD4+ T cells (defined as 
CD45RA+CCR7+CD4+) were isolated (>98% purity) with a FACS Aria (BD Biosciences) 
machine from healthy controls or patients. They were then cultured under polarizing 
conditions, as previously described (64). Briefly, cells were cultured with TAE beads alone 
or under Th1 (IL-12 [20 ng/ml; R&D Systems]), Th2 (IL-4 [100 U/ml]; anti-IFN-γ [5 
µg/ml; eBioscience]) was also included in some cultures) or Th17 (TGFb, IL-1β [20 ng/ml; 
Peprotech], IL-6 [50 ng/ml; PeproTech], IL-21 [50 ng/ml; PeproTech], IL-23 [20 ng/ml; 
eBioscience], anti-IL-4 [5 µg/ml], and anti-IFN-γ [5 µg/ml; eBioscience]) polarizing 
conditions. After 5 days, culture supernatants were used to assess the secretion of the 
cytokines indicated, by ELISA (IL-22) or with cytometric bead arrays (all other cytokines). 
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T-cell libraries: Two subsets of CD45RA–CD25–CD19–CD8–CD4+ memory T cells were 
sorted from total PBMC with a FACS Aria machine (BD Biosciences) on the basis of 
CCR6 expression. CD45RA+CCR7+ naïve cells were excluded. The CCR6+ subset 
included Th1* and Th17 cells, whereas the CCR6– subset included Th1 and Th2 cells (65). 
The sorted memory CCR6– T cells were used to seed culture plates at a density of 600 
cells/well, and CCR6+ cells were used to seed plates at a density of 150-300 cells/well. The 
cells were cultured in RPMI 1640 medium supplemented with 2 mM glutamine, 1% 
(vol/vol) non-essential amino acids, 1% (vol/vol) sodium pyruvate, penicillin (50 U/ml), 
streptomycin (50 µg/ml) (all from Invitrogen) and 5% heat-inactivated human serum 
(Swiss Red Cross). All wells were polyclonally stimulated with 1 µg/ml PHA (Remel) in 
the presence of irradiated (45 Gy) allogeneic PBMCs as feeder cells (2.5 × 104 per well) 
and IL-2 (500 IU/ml), in a 96-well plate, and T-cell lines were expanded in the presence of 
IL-2, as previously described (37). After 13-16 days, a small volume of cells from three 
CCR6– or CCR6+ lines from each patient were pooled and tested for their ability to produce 
IFN-g, IL-17A, IL-22 or IL-4, by intracellular staining (ICS) after stimulation with PMA 
(200 nM) and ionomycin (1 µg/ml) (Sigma-Aldrich). The screening of the T cell lines was 
performed 18-22 days after initial stimulation, by culturing thoroughly washed T cells (2.5 
× 105/well) with autologous irradiated B cells (2.5 × 104), with or without a three-hour 
pulse with different antigens, including the M. tuberculosis peptide pool (0.5 
µg/ml/peptide, from A. Sette’s laboratory, LJI, comprising 207 peptides), the BCG peptide 
pool (0.5 µg/ml/peptide, from A. Sette’s laboratory, LJI, comprising 211 peptides), the 
respiratory syncytial virus (RSV) peptide pool (1 µg/ml/peptide, from A. Sette’s 
laboratory, LJI, comprising 190 peptides), and influenza virus (Influvac vaccine). 
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Proliferation was assessed on day 4, after incubation for 16 h with 1 µCi/ml [3H]-thymidine 
(GE Healthcare). Cytokine concentrations in the culture supernatants were determined after 
48 h of stimulation, in Luminex multiplex cytokine assays (Thermo Fisher). Precursor 
frequencies were calculated from the number of negative wells, assuming a Poisson 
distribution, and are expressed per million cells (66). 
 
Purification of the leukocyte population by magnetic-activated cell sorting (MACS): Age-
matched healthy donor PBMCs were stained with microbead-conjugated antibodies 
directed against CD20, CD56, CD8 or CD4 (Miltenyi Biotec), according to the 
manufacturer’s protocol, or biotin-conjugated anti-gdTCR (331206: Biolegend); they were 
then washed in PBS, then stained with anti-biotin microbeads (Miltenyi Biotec). Labeled 
cells were purified by passing the cell suspension through MS columns (Miltenyi Biotec) 
and retaining the eluate. The purity of each cell population was shown, by flow cytometry, 
to be ³92%. Leukocytes were then stimulated with rhIL-12 (20 ng/ml; R&D Systems), 
rhIL-23 (100 ng/ml; R&D Systems), or PMA and ionomycin (20 µg/ml and 1 µM) for 6 h. 
 
Leukocyte purification by FACS sorting: Healthy donor PBMCs were stained with 
Live/Dead fixable aqua (Invitrogen), anti-CD3 V450 (560365: BD Biosciences), anti-
CD161 FITC (339923: Biolegend), anti-Vα24Jα PerCPeF710 (46-5806-42: eBiosciences) 
and anti-Vα7.2 APC (351724: Biolegend). MAIT cells were sorted on a FACS Aria II 
machine (BD Biosciences) with gating on CD3+CD161+Vα7.2+ cells. NKT cells were 
sorted as CD3+Vα24Jα+ cells. Sorted MAIT or NKT cells (>95% purity) were then 
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stimulated with rhIL-12 (20 ng/ml; R&D Systems), rhIL-23 (100 ng/ml; R&D Systems), 
or PMA and ionomycin (20 µg/ml and 1 µM) for 6 h.  
 
mRNA isolation, microarray, and quantitative RT-PCR: mRNA was prepared with the ZR 
RNA microprep kit (Zymo Research), according to the manufacturer’s protocol. mRNA 
samples were used to prepare biotinylated ss-cDNA fragments with the GeneChip® Whole 
Transcript PLUS Reagent Kit (Affymetrix), which were then hybridized to a GeneChip® 
Human Transcriptome 2.0 array (Affymetrix), according to the manufacturers’ 
instructions. Data were analyzed with Affymetrix® Expression ConsoleTM and 
Transcription Analysis Console software. PBMCs from three other healthy age-matched 
donors were stimulated as described above, mRNA was isolated and reverse transcription-
PCR was performed with oligo-dT primers, according to the manufacturer’s protocol 
(Applied Biosystems, Foster City, CA). Quantitative real-time PCR (qPCR) was performed 
with Applied Biosystems Taqman assays and exon-spanning probes directed against IFNG, 
IL12RB2, IL12RB1 and IL23R, with normalization against β-glucuronidase (GUS), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), or 18S housekeeping genes.   
 
Whole-blood activation experiments: Venous blood samples from healthy controls and 
from patients were collected into heparin-containing tubes and processed according a 
modified version of the procedure described by Feinberg et al. (38). Briefly, they were 
diluted 1:2 in RPMI1640 (GibcoBRL) supplemented with 100 U/ml penicillin and 100 
µg/ml streptomycin (GibcoBRL). We dispensed 5 ml of diluted blood sample into each of 
5 wells (1 ml/well) of a 48-well plate (Nunc). These samples were incubated for 48 h at 
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37°C, under an atmosphere containing 5% CO2/95% air, and under three different sets of 
activation conditions: with medium alone, with live BCG (M. bovis-BCG, Pasteur 
substrain) at a MOI of 20 BCG bacteria/leukocyte, or with BCG plus recombinant (rh) IL-
12 (20 ng/ml; R&D Systems). ELISA was performed on the collected supernatants, with 
the human IFN-g ELISA Kit (Sanquin), according to the manufacturer’s instructions. 
 
PBMC activation experiments: PBMCs were isolated from buffy coats and used at a 
density of 106/ml in RPMI medium supplemented with 10% FBS. Cells were treated with 
rhIL-12 (20 ng/ml; R&D Systems), rhIL-23 (100 ng/ml; R&D Systems), or live BCG (M. 
bovis BCG, Pasteur substrain) at a MOI of 20 BCG cells/leukocyte, or PMA plus 
ionomycin (20 µg/ml and 1 µM) in for 48 h. All experiments were performed in triplicate 
wells. Cell culture supernatants were removed and used for multiplex cytokine detection 
with the V-PLEX Human Proinflammatory cytokine panel assay (Meso Scale Discovery). 
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Supplementary figure legends 
Supplementary Figure 1: Clinical and genetic features of kindreds with autosomal 
recessive IL-12Rb2 or IL-23R deficiency.  
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A) Histology of a lymph node biopsy specimen for P1 (IL-12Rb2 Q138X) showing 
epithelioid and multinucleated giant cells at the periphery of a necrotic area. B) Histology 
of a lymph node biopsy specimen for P5 (IL-23R C115Y) showing follicular hyperplasia 
and the presence of small ill-defined macrophagic granulomas. C) Gross anatomical 
depiction of the chest mass resulting from Mycobacterium bovis-BCG infection in P5 at 
the age of four years. D) CT scan of the chest, cross-sectional view, showing a mediastinal 
mass, in P5 at the age of four years. E, F) Whole-genome linkage (WGL) analysis of 
kindred A (E) and kindred B (F). LOD scores are shown in black and blue for alternating 
chromosomes, and information content is shown with a red trace. Both IL12RB2 and IL23R 
map to the linked region of chromosome 1 indicated with an arrow. G) Schematic 
representation of the region of chromosome 1 containing IL12RB2 and IL23R, located head 
to tail. Each arrow represents a gene, IL23R in red and IL12RB2 in blue. The direction of 
the arrow indicates the orientation of the gene on the chromosome. The locations of the 
first and last nucleotide of each gene are indicated underneath the diagram. The horizontal 
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line represents the corresponding part of chromosome 1 and the vertical lines within each 
arrow indicate exon positions. H, I) Representative electrophoretograms corresponding to 
a WT individual, a heterozygous carrier and a homozygous carrier of the IL12RB2-Q138X 
(H) and IL23R-C115Y (I) mutations. The electrophoretograms shown are from the 
underlined individuals in Fig 1A-B. J) Principal component analysis (PCA) was performed 
as explained in Materials and Methods using 2,504 individuals of the 1000 Genomes 
Project classified in 5 populations (African (AFR), American (AMR), East Asian (EAS), 
European (EUR), South Asian(SAS)), and 3752 individuals of diverse ethnic origin from 
our in-house exome database (IHE). The two affected index cases, P1 homozygous for 
IL12RB2 Q138X, and P4 homozygous for IL23R C115Y are shown (black diamonds). The 
two patients are located within clusters of individuals of our in house database who share 
the same origin (Turkish, and Iranian, respectively). The proportions of the variance 
explained by principal components (PC)1 and PC2 are shown in parentheses. K) LCL-
BSTAT4 cells were either left non-transduced (NT) or were transduced with a retrovirus 
generated with an empty vector (EV) or with a vector containing the WT or mutant V5-
tagged IL12RB2 or IL23R. Levels of IL12RB2, IL12RB1 and IL23R mRNA were 
determined by RT-qPCR. L) Western blot of lysates from the same cells as in (J) with 
antibodies against the V5-tag, and GAPDH as the loading control.  M) LCL-BSTAT4 cells 
either non-transduced (NT) or transduced with retroviruses generated with an empty vector 
(EV) or with vectors containing V5-tagged WT or C115Y mutant versions of IL23R. Cells 
were then left unstained (gray trace), or were stained with an avidin-PE antibody only (blue 
trace), or an IL-23R-biotin antibody, washed and stained with an avidin-PE anybody (red 
trace). PE fluorescence is shown on the x-axis. 
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Supplementary Figure 2: IL12RB2 Q138X and IL23R C115Y mutations abolish the 
response of the encoded receptor to its cognate cytokine ligand.  
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A) Western blot analysis of the same lysates as in Fig. 1I, with antibodies against 
phosphorylated STAT4, total STAT4 and GAPDH as a loading control. B) LCL-BSTAT4 
cells either non-transduced (NT) or transduced with retroviruses generated with an empty 
vector (EV) or vectors containing V5-tagged WT or C115Y mutant versions of IL23R, 
were either left unstimulated or were stimulated with IL-23 or IFN-α as a positive control. 
Lysates were analyzed by western blotting with antibodies against phosphorylated STAT3, 
total STAT3, phosphorylated TYK2, total TYK2, phosphorylated JAK2, total JAK2, and 
GAPDH as a loading control. C) LCL-BSTAT4 cells were either left non-transduced (NT), 
or were transduced with retroviruses generated with an empty vector (EV) or vectors 
containing V5-tagged WT or Q138X mutant versions of IL12RB2, or WT or C115Y 
versions of IL23R. Cells were either left unstimulated, or stimulated with IL-12 or IL-23. 
After 24 h, the CXCL10 in the cell supernatant was determined by ELISA, and is expressed 
as a fold-change relative to unstimulated cells. D) The same cells as in (B) were either left 
unstimulated or were stimulated with IL-23 or IFN-α after 48 h of pretreatment with the 
glycosylation inhibitor kifunensine. Lysates were analyzed by western blotting with 
antibodies against pSTAT3, total STAT3 or GAPDH. E) HVS-T cells from a healthy 
control, the three IL-12Rβ2-deficient patients and an IL-12Rβ1-deficient patient were 
either left unstimulated or were stimulated with IL-12 or IFN-α as a positive control. They 
were then lysed and the lysates were subjected to western blotting with antibodies against 
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phosphorylated STAT4, total STAT4 and GAPDH as a loading control. F) FACS plots 
showing EBV-B cells from a representative healthy control, P4, P4 cells transduced with a 
retrovirus generated with an empty vector, or a vector containing WT IL23R, either 
unstained or stained for IL-23R. G) Percentage of EBV-B cells positive for IL-23R, for 9 
healthy controls, P4, P4 cells transduced with a retrovirus generated with an empty vector 
(EV) or with a vector containing IL23R-WT, an IL-12Rβ- deficient patient and a TYK2-
deficient patient. H) EBV-B cells from a healthy control (C+) P4, P4 cells transduced with 
a retrovirus containing IL23R-WT, an IL-12Rβ1-deficient patient and a TYK2-deficient 
patient were either left unstimulated or were stimulated with IL-23 or IFN-α as a positive 
control. The cells were lysed and the lysates were subjected to western blotting with 
antibodies against phosphorylated STAT3, STAT3 or GAPDH as a loading control. I) 
EBV-B cells from a healthy control, an IL-12Rβ1-deficient patient and P4 were either left 
unstimulated or were stimulated with IL-23 in the presence or absence of kifunensine. IFN-
α stimulation was used as a positive control. Lysates were analyzed by western blotting 
with antibodies against phosphorylated STAT3, total STAT3 and GAPDH as a loading 
control. J) In parallel, as a control for kifunensine function, EBV-B cells from a healthy 
control and a patient  carrying the loss-of-function IFNGR2-382-387dup mutation 
previously reported to be rescued by kifunensine treatment (28), were stimulated with IL-
23 in the presence or absence of kifunensine, or with IFN-α as a positive control. The cells 
were lysed and the lysates were subjected to western blotting with antibodies against 
phosphorylated STAT1, total STAT1 and GAPDH as a loading control. 
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Supplementary Figure 3: Population genetics for IL12RB1, IL12RB2 and IL23R.  
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A) CADD score (y-axis) vs. minor allele frequency (MAF, x-axis) for all the heterozygous 
variants of IL12RB2 found in gnomAD. The mutation studied here (Q138X) is shown in 
blue. Missense variants are shown in black and variants predicted to be loss-of-function 
(LOF; stop loss, start loss, nonsense, inframe indels, frameshift indels and essential 
splicing) are shown in green. B) CADD score (y-axis) vs. MAF (x-axis), for all the 
heterozygous variants of IL23R found in gnomAD. The mutation studied here (C115Y) is 
shown in red. Missense variants are shown in black and variants predicted to be LOF (stop 
loss, start loss, nonsense, inframe indels, frameshift indels and essential splicing) are shown 
in green. C, D) CADD score (y-axis) vs. MAF (x-axis) for all the heterozygous (C) and 
homozygous (D) variants of IL12RB1 found in gnomAD. Missense variants are shown in 
black, and variants predicted to be LOF (stop loss, start loss, nonsense, inframe indels, 
frameshift indels and essential splicing) are shown in green. Variants previously 
demonstrated to impair or abolish IL-12Rβ1 function (LoF) are shown in purple. E) 
Schematic representation of IL-12Rβ2. Rectangles represent individual exons of the gene, 
with exon numbers indicated within the rectangles. The N-terminal portion of the protein 
is the extracellular domain, and gray shaded areas represent the transmembrane domain. 
The Q138X mutation identified in kindred A is shown in blue. IL12RB2 variants tested by 
de Paus et al. and shown to be functional are shown in green (27). The L130S variant, 
	 53 
which is LOF (refer to Fig. 2E) is shown in orange and all the other variants present in the 
homozygous state in the gnomAD database are shown in black. F) Schematic 
representation of IL-23R. Rectangles represent individual exons of the gene with the exon 
numbers indicated within the rectangles. The N terminal portion of the protein is the 
extracellular domain, and gray shaded areas represent the transmembrane domain. The 
C115Y mutation identified in kindred B is shown in red. Variants present in the 
homozygous state in the gnomAD database are shown in black. G) LCL-BSTAT4 cells were 
either left non-transduced (NT) or were transduced with a retrovirus generated with an 
empty vector (EV), a vector containing WT IL12RB2, or vectors containing all the 
homozygous IL12RB2 variants reported in gnomAD and represented in Fig. 2C plus a 
plasmid containing the gene sequence but with the deletion of exon 15 described in (H, I). 
Lysates from these transduced cells were analyzed by western blotting with antibodies 
against the V5-tag and GAPDH as the loading control. H) cDNA was prepared from HVS-
T cells from a WT donor, and from an individual heterozygous for the IL12RB2 variant 
c.1947G>C. This variant may cause alternative splicing and the K649N substitution. The 
cDNA was amplified by PCR with primers specific to exons 14 and 16. The PCR product 
from HVS-T cells heterozygous for IL12RB2 c.1947G>C gave an additional band of lower 
molecular weight than the WT individual, and this band corresponded to the skipping of 
exon 15 (Δex15). I) Using the same primers as in (H), RT-PCR was performed on PHA 
blasts from two WT and one heterozygous carrier of c.1947G>C, and HVS-T cells from a 
WT individual and a heterozygous carrier of c.1947G>C. PCR products were inserted into 
a pGEM-T easy vector that was then used to transform competent bacteria. Individual 
colonies were grown, and plasmid DNA was extracted and sequenced. This table shows 
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the observed IL12RB2 genotypes corresponding to the PCR products obtained.  J) LCL-
BSTAT4 cells were either left non-transduced (NT) or were transduced with a retrovirus 
generated with an empty vector, a vector containing WT IL23R, or vectors containing the 
homozygous IL23R variants reported in gnomAD and represented in Fig. 2D. Lysates from 
these transduced cells were analyzed by WB with antibodies against V5-tag, and GAPDH 
as a loading control.  
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Supplementary Figure 4: Immunophenotype of IL-12Rβ2-, IL-12Rβ1- and IL-23R-
deficient patients.  
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A) Frequencies of B, NK, γδT, ILC, NKT, MAIT, CD3+, Tregs, Tfh, CD4+ and CD8+ cells 
for healthy controls (black), IL-12Rβ2-Q138X (blue), IL-23R-C115Y (red) and IL-12Rβ1-
deficient patients (gray). B) On the left, frequencies of naïve and memory cells, as a 
percentage of total CD8+ T cells. On the right, frequencies of naïve (CCR7+CD45RA+), 
central memory (CCR7+CD45RA–), effector memory (CCR7–CD45RA–) and TEMRA 
(CCR7–CD45RA+) T cells as percentage of total CD8+ T cells. Error bars indicate the SEM. 
C) Frequencies of naïve and memory cells, as a percentage of total CD4+ T cells. D) 
Frequencies of four subsets of CD4+ memory T cells (CD3+CD45RA–): Th1 (CCR6–
CCR4–CXCR3+), Th1* (CCR6+CCR4–CXCR3+), Th17 (CCR6+CCR4+CXCR3–) and Th2 
(CCR6–CCR4+CXCR3–) were measured and expressed as a percentage of total CD4+ 
memory T cells (CD3+CD45RA–). Error bars indicate the SEM. P values for the 
comparison of healthy controls with IL12RB1-/- individuals in Mann-Whitney U-tests are 
shown.  
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Supplementary Figure 5: Non-antigen-specific cytokine production, and antigen-
specific proliferation, precursor frequency, and cytokine production by CD4+ 
memory T cells from healthy controls, IL-12Rβ2-, IL-23R- and IL-12Rβ1-deficient 
patients.  
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A) CCR6+ or CCR6- memory CD4+ T cell lines were generated from healthy controls 
(n=5), one IL-12Rβ2-Q138X patient, one IL-23R-C115Y patient, and four IL-12Rβ1-
deficient patients. Stimulation with PMA + ionomycin was performed on pooled T-cell 
lines from each patient, and the frequency of cells positive for the indicated cytokines was 
assessed by intracellular flow cytometry. B) Proliferation, measured by 3H-thymidine 
incorporation, of CD4+CCR6– (upper panels) and CD4+CCR6+ (lower panels) T-cell lines 
stimulated by autologous B cells pulsed with influenza virus, RSV, BCG or MTB peptide 
pools. Healthy controls are indicated in black, IL-12Rβ2-Q138X in blue, IL-23R-C115Y 
in red and IL-12Rβ1-deficient patients in gray. C) Frequency (mean number per million) 
of RSV-, influenza virus-, BCG- and MTB-specific memory T cells within the 
CD4+CCR6– (left panel) and CD4+CCR6+ (right panel) subsets in healthy controls (black), 
IL-12Rβ2-Q138X (blue), IL-23R-C115Y (red) and IL-12Rβ1-deficient patients (gray), 
assuming a Poisson distribution. D) IL-4 and IFN-γ production by influenza virus- and 
RSV-specific CD4+CCR6– memory T cells.  
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Supplementary Figure 6: Cytokine receptor expression and responses of MAIT and 
NKT cells to stimulation with IL-12 or IL-23.  
 
A) RT-qPCR for IL12RB2, IL12RB1 and IL23R in B, CD4+, CD8+, γδT, NK, NKT and 
MAIT cells from Fig. 4E represented as relative expression, normalized against GUS. B) 
Whole blood was either left non-stimulated or was stimulated with IL-12, BCG or IL-
12+BCG, and IFN-γ was determined 48 h after stimulation. C) Whole blood was either left 
non-stimulated or was stimulated with IFN-γ, BCG or IFN-γ +BCG, and IL-12p40 (left) 
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and IL-12p70 (right) were determined 48 h after stimulation. D) PBMCs from healthy 
controls and IL-12Rβ1-deficient patients were either left non-stimulated or were stimulated 
for 48 h with IL-12, IL-23, BCG, IL-12+BCG, IL-23+BCG or PMA+I, and IFN-γ was then 
determined. 
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Supplementary Table 1: Estimated proportions of deleterious and non-deleterious 
amino-acid variants in IL12RB1, IL12RB2 and IL23R.  
 IL12RB1 IL12RB2 IL23R 
Fixed synonymous 9 11 
 
7 
 
Polymorphic synonymous 15 
 
15 
 
7 
 
Fixed nonsynonymous 
 
5 6 6 
Polymorphic 
nonsynonymous 
 
18 36 14 
Synonymous sites 
 
447.7 
 
580 
 
395.7 
 
Nonsynonymous sites 
 
1426.3 
 
2009 
 
1494.3 
 
f estimate 
 
46.7% [30.4% - 
71.7%] 
 
61.7% [42.1% - 
90.3%] 
 
49.0% [31.1% 
- 77.4%] 
 
Genome-wide rank 
 
50.0% 
 
85.3% 
 
57.0% 
 
g estimate 
 
-0.77 [-1.32 –  
-0.22] 
-0.85 [-1.36 –  
-0.35] 
 
-0.58 [-1.12 – 
-0.05] 
 
Genome-wide rank 
 
56.4% 47.9% 
 
73.8% 
 
 
 
Supplementary Table 2: Please refer to Auxiliary Supporting Materials and Other 
Supporting Files  
 
Supplementary Table 3: Please refer to Auxiliary Supporting Materials and Other 
Supporting Files 
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Supplementary Table 4: Relative levels of IFN-g production in response to IL-12 vs. 
IL-23 in different cell subsets. 
Population IL-12 (20 ng/ml) IL-23 (100 ng/ml) 
B - - 
CD4+ T ++ + 
CD8+ T ++ + 
γδT +++ ++ 
NK ++++ + 
MAIT + +++ 
NKT + +++ 
ILC1* ++ - 
ILC2* + - 
ILC3* - + 
*Different stimulation conditions (as in Fig 4A) 
 
 
